Snapshot · The Peter Attia Drive
People with genetic CETP loss-of-function variants have lower rates of Alzheimer's disease and cognitive impairment, providing the biological rationale for testing CETP inhibitors as a neuroprotective strategy.
Where this was said
At 1:31:56 · chapter starts 1:31:00
Peter closes the pharmacology discussion with the most forward-looking topic: obicetrapib, a CETP inhibitor that inhibits the transfer of cholesterol from HDL to ApoB particles, causing HDL to enlarge and ApoA-1 to rise. The biological rationale for neuroprotection comes from genetics: people with natural CETP loss-of-function variants have lower rates of Alzheimer's disease and cognitive impairment. Pharmacologically mimicking this state could theoretically confer the same benefit [1] — Tom Dayspring "Obicetrapib, a CETP inhibitor, raises ApoA-1 and generates tiny protein-rich HDL particles that can cross the blood-brain barrier. The BROA…" 1:31:50 . Tom explains the cascade: obicetrapib enlarges HDL particles, the liver interprets the reduced free ApoA-1 as a deficiency and ramps up ApoA-1 production, and circulating ApoA-1 rises. These free ApoA-1 molecules and the tiny protein-rich HDL particles they form can cross the blood-brain barrier, fuse with brain ApoE HDL particles, and potentially convert dysfunctional APOE4 brain HDL into functional units capable of properly delivering cholesterol to neurons. The BROADWAY trial, conducted primarily for cardiovascular endpoints, measured Alzheimer's biomarkers — phosphorylated tau, amyloid-40/42 ratios, and fibrillary markers — and found movement in the right direction. New Amsterdam Pharma is now planning further trials with cognitive endpoints and possibly PET imaging. Tom and Peter are cautiously optimistic, noting that getting the timing and patient selection right — catching APOE4 carriers before irreversible pathology accumulates — will be the key challenge, citing the PREDIMED trial's early-halt success as a model for well-targeted primary prevention.
Researcher Bill Harris has concluded that an omega-3 index of 8–9% in red blood cell membranes reflects adequate omega-3 content across the body's cell membranes, though no randomized trial has proven a specific brain benefit.
Obicetrapib, a CETP inhibitor, raises ApoA-1 and generates tiny protein-rich HDL particles that can cross the blood-brain barrier. The BROADWAY trial showed movement in the right direction on phosphorylated tau, amyloid-40/42 ratios, and other Alzheimer's biomarkers — suggesting it may rescue dysfunctional APOE4 brain HDL.
Spencer Greenberg and Jeremy Stevenson analyzed almost 500 self-improvement techniques and found they all reduce to just 12 underlying psychological drivers.
Cold exposure has good short-term alertness benefits but the evidence base for long-term health benefits is much weaker than popularly believed.
In a randomized study of 20 habit-formation techniques run on hundreds of people, almost none of the techniques produced statistically meaningful results.
People given a tiny-habit fallback option (e.g. 10 squats instead of gym) were actually MORE successful at completing the full habit, not less.
The most effective habit-formation technique was 'habit reflection' — recalling a past successful habit, writing down what helped, then applying those lessons to a new habit.
A study found that simply scheduling enjoyable activities was as effective as standard cognitive behavioral therapy for depression, leading to its own therapy called behavioral activation.
The 'worry time' technique — deferring all worries to a designated time of day — helps people realize they have more control over worry than they thought and reveals it is less useful than it feels.
A study found that participants told to try to stay awake while in bed fell asleep faster than participants told to try to sleep — illustrating the paradox of direct effort.
Spencer Greenberg reduced his severe social anxiety dramatically in roughly 6 months through a structured exposure therapy hierarchy, culminating in asking strangers for hugs.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.